Literature DB >> 26011521

Meta-analysis of rate ratios with differential follow-up by treatment arm: inferring comparative effectiveness of medical devices.

Lauren M Kunz1,2, Sharon-Lise T Normand2,3, Art Sedrakyan4.   

Abstract

Modeling events requires accounting for differential follow-up duration, especially when combining randomized and observational studies. Although events occur at any point over a follow-up period and censoring occurs throughout, most applied researchers use odds ratios as association measures, assuming follow-up duration is similar across treatment groups. We derive the bias of the rate ratio when incorrectly assuming equal follow-up duration in the single study binary treatment setting. Simulations illustrate bias, efficiency, and coverage and demonstrate that bias and coverage worsen rapidly as the ratio of follow-up duration between arms moves away from one. Combining study rate ratios with hierarchical Poisson regression models, we examine bias and coverage for the overall rate ratio via simulation in three cases: when average arm-specific follow-up duration is available for all studies, some studies, and no study. In the null case, bias and coverage are poor when the study average follow-up is used and improve even if some arm-specific follow-up information is available. As the rate ratio gets further from the null, bias and coverage remain poor. We investigate the effectiveness of cardiac resynchronization therapy devices compared with those with cardioverter-defibrillator capacity where three of eight studies report arm-specific follow-up duration.
Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  aggregated data; bayesian; comparative effectiveness

Mesh:

Year:  2015        PMID: 26011521      PMCID: PMC4523415          DOI: 10.1002/sim.6530

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  17 in total

1.  Network meta-analysis for indirect treatment comparisons.

Authors:  Thomas Lumley
Journal:  Stat Med       Date:  2002-08-30       Impact factor: 2.373

2.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

Authors:  M K Parmar; V Torri; L Stewart
Journal:  Stat Med       Date:  1998-12-30       Impact factor: 2.373

3.  A new form of meta-analysis for combining results from randomized clinical trials and medical-practice databases.

Authors:  J Droitcour; G Silberman; E Chelimsky
Journal:  Int J Technol Assess Health Care       Date:  1993       Impact factor: 2.188

Review 4.  Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.

Authors:  D F Stroup; J A Berlin; S C Morton; I Olkin; G D Williamson; D Rennie; D Moher; B J Becker; T A Sipe; S B Thacker
Journal:  JAMA       Date:  2000-04-19       Impact factor: 56.272

5.  The hazards of hazard ratios.

Authors:  Miguel A Hernán
Journal:  Epidemiology       Date:  2010-01       Impact factor: 4.822

6.  Biventricular implantable cardioverter defibrillators improve survival compared with biventricular pacing alone in patients with severe left ventricular dysfunction.

Authors:  Cengiz Ermis; Keith G Lurie; Alan X Zhu; Joanne Collins; Laura Vanheel; Scott Sakaguchi; Fei Lu; Scott Pham; David G Benditt
Journal:  J Cardiovasc Electrophysiol       Date:  2004-08

7.  Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial.

Authors:  Beth S Woods; Neil Hawkins; David A Scott
Journal:  BMC Med Res Methodol       Date:  2010-06-10       Impact factor: 4.615

8.  Lead complications, device infections, and clinical outcomes in the first year after implantation of cardiac resynchronization therapy-defibrillator and cardiac resynchronization therapy-pacemaker.

Authors:  Andreas Schuchert; Carmine Muto; Themistoklis Maounis; Robert Frank; Eric Boulogne; Alexander Polauck; Luigi Padeletti
Journal:  Europace       Date:  2012-08-26       Impact factor: 5.214

9.  Long-term outcomes of CRT-PM versus CRT-D recipients.

Authors:  Giuseppe Stabile; Francesco Solimene; Emanuele Bertaglia; Vincenzo La Rocca; Michele Accogli; Alberto Scaccia; Natale Marrazzo; Franco Zoppo; Pietro Turco; Assunta Iuliano; Gergana Shopova; Carmine Ciardiello; Antonio De Simone
Journal:  Pacing Clin Electrophysiol       Date:  2009-03       Impact factor: 1.976

10.  Practical methods for incorporating summary time-to-event data into meta-analysis.

Authors:  Jayne F Tierney; Lesley A Stewart; Davina Ghersi; Sarah Burdett; Matthew R Sydes
Journal:  Trials       Date:  2007-06-07       Impact factor: 2.279

View more
  5 in total

1.  Meta-Analysis Comparing Complete Versus Infarct-Related Artery Revascularization in Patients With ST-Elevation Myocardial Infarction and Multivessel Coronary Disease.

Authors:  Mohammed Osman; Safi U Khan; Peter D Farjo; Noor Chima; Babikir Kheiri; Firas Zahr; Mohamad Alkhouli
Journal:  Am J Cardiol       Date:  2019-11-19       Impact factor: 2.778

Review 2.  Systematic Review with Meta-Analysis: Comparison of the Risk of Hepatocellular Carcinoma in Antiviral-Naive Chronic Hepatitis B Patients Treated with Entecavir versus Tenofovir: The Devil in the Detail.

Authors:  Hyunwoo Oh; Hyo Young Lee; Jihye Kim; Yoon Jun Kim
Journal:  Cancers (Basel)       Date:  2022-05-25       Impact factor: 6.575

3.  Comparative effectiveness of cardiac implantable electrical devices.

Authors:  Daniel B Kramer; Laura A Hatfield; Sharon-Lise T Normand
Journal:  Heart       Date:  2015-08-24       Impact factor: 5.994

4.  The ratio of the seroprevalence to the egg-positive prevalence of Schistosoma japonicum in China: a meta-analysis.

Authors:  Yao Deng; Chen Qiu; Huan Ding; Da-Bing Lu
Journal:  BMC Infect Dis       Date:  2018-08-15       Impact factor: 3.090

5.  Limitations of the incidence density ratio as approximation of the hazard ratio.

Authors:  Ralf Bender; Lars Beckmann
Journal:  Trials       Date:  2019-08-08       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.